Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Falchi

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Cancer|September 12, 2013
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical CenterLorenzo Falchi, Michael J Keating, Xuemei Wang, et al.
Journal of Geriatric Oncology|April 22, 2019
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignanciesCandida Vitale, Lorenzo Falchi, Maria Ciccone, et al.
European Journal of Haematology|October 3, 2007
A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapyLorenzo Falchi, Daniela Capello, Barbara Palumbo, et al.
Cancers|January 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I StudyErel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi, et al.
Journal of Hematology & Oncology|December 1, 2016
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapyLorenzo Falchi, Ahmed Sawas, Changchun Deng, et al.
Blood|June 30, 2012
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African AmericansCatherine C Coombs, Laura Z Rassenti, Lorenzo Falchi, et al.
Haematologica|May 14, 2026
CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatmentPranya Gaddipati, Ahmed Ayad, Zachary Epstein-Peterson, et al.
Oncoimmunology|July 8, 2026
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphomaLorenzo Falchi, Martin Hutchings, David Tybor, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life ExperienceMarina Moretti, Anna Marina Liberati, Luigi Rigacci, et al.
Molecular Cancer Therapeutics|June 10, 2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysLuigi Scotto, Cristina Kinahan, Eugene Douglass, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Cancer|September 12, 2013
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical CenterLorenzo Falchi, Michael J Keating, Xuemei Wang, et al.
Journal of Geriatric Oncology|April 22, 2019
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignanciesCandida Vitale, Lorenzo Falchi, Maria Ciccone, et al.
European Journal of Haematology|October 3, 2007
A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapyLorenzo Falchi, Daniela Capello, Barbara Palumbo, et al.
Cancers|January 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I StudyErel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi, et al.
Journal of Hematology & Oncology|December 1, 2016
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapyLorenzo Falchi, Ahmed Sawas, Changchun Deng, et al.
Blood|June 30, 2012
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African AmericansCatherine C Coombs, Laura Z Rassenti, Lorenzo Falchi, et al.
Haematologica|May 14, 2026
CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatmentPranya Gaddipati, Ahmed Ayad, Zachary Epstein-Peterson, et al.
Oncoimmunology|July 8, 2026
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphomaLorenzo Falchi, Martin Hutchings, David Tybor, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life ExperienceMarina Moretti, Anna Marina Liberati, Luigi Rigacci, et al.
Molecular Cancer Therapeutics|June 10, 2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysLuigi Scotto, Cristina Kinahan, Eugene Douglass, et al.
Pageof 8